Tico trial5/28/2023 ![]() Patients undergoing BP-SES implantation for ACS treatment will be randomized in a 1:1 fashion to the (1) ticagrelor monotherapy group after 3-month DAPT or the (2) 12-month DAPT group. The TICO randomized open-label trial will evaluate whether ticagrelor monotherapy following 3-month DAPT is superior to 12-month ticagrelor-based DAPT in terms of net adverse clinical events (NACE) including efficacy and safety in ACS patients treated with ultrathin bioresorbable polymer sirolimus-eluting stents (BP-SES). ![]() Ticagrelor monotherapy after short-term dual-antiplatelet therapy (DAPT) may optimize ischemic and bleeding risks, particularly for acute coronary syndrome (ACS) patients, because its strategy is less potent than ticagrelor-based DAPT but more potent than aspirin or clopidogrel monotherapy. Electronic address: 4 Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. 3 Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.2 Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. ![]() ![]() 1 Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. ![]()
0 Comments
Leave a Reply. |